SCHEMBL4334322

SCHEMBL4334322

CCC(c1ccccc1)N1CCCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.66
CYP2C19 P33261 6/20 0.66
CYP3A4 P08684 5/20 0.66
CYP2D6 P10635 5/20 0.66
TSHR P16473 1/20 0.66
CYP2C9 P11712 5/20 0.62
KCNA5 P22460 4/20 0.62
KCNH2 Q12809 4/20 0.62
KCNE1 P15382 1/20 0.62
OPRD1 P41143 4/20 0.59
OPRM1 P35372 3/20 0.59
OPRK1 P41145 3/20 0.59
OPRL1 P41146 3/20 0.59
HPGD P15428 1/20 0.57
MAPK1 P28482 1/20 0.57
ALDH1A1 P00352 1/20 0.54
MC4R P32245 3/20 0.49
GAA P10253 1/20 0.47
HRH3 Q9Y5N1 2/20 0.47
SLC6A2 P23975 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8922757 1.00 CYP1A2 (0.66) CYP1A2CYP2C19CYP3A4CYP2D6TSHR
SCHEMBL8916036 0.98 CYP1A2 (0.62) CYP1A2CYP2C19CYP3A4CYP2D6TSHR
SCHEMBL1964502 0.98 CYP1A2 (0.62) CYP1A2CYP2C19CYP3A4CYP2D6TSHR
SCHEMBL30364119 0.94 OPRM1 (0.61) CYP1A2CYP2C19CYP3A4CYP2D6TSHR
SCHEMBL30363975 0.94 OPRM1 (0.61) CYP1A2CYP2C19CYP3A4CYP2D6TSHR
SCHEMBL2962625 0.90 OPRM1 (0.65) CYP1A2CYP2C19CYP3A4CYP2D6TSHR
SCHEMBL113896 0.85 CYP1A2 (0.62) CYP1A2CYP2C19CYP3A4CYP2D6TSHR
SCHEMBL10601133 0.85 CYP1A2 (0.62) CYP1A2CYP2C19CYP3A4CYP2D6TSHR
SCHEMBL3246700 0.83 SLC6A4 (0.63) CYP1A2CYP2C19CYP3A4CYP2D6CYP2C9
SCHEMBL10598753 0.83 OPRM1 (0.63) CYP1A2CYP2C19CYP3A4CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233858-B1 ERK INHIBITORS MERCK SHARP & DOHME (US) 2019-10-30 EP disclosed
US-20170266167-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 US disclosed
US-8445480-B2 CETP inhibitors derived from benzoxazole arylamides MERCK SHARP & DOHME CORP. (US) 2013-05-21 US disclosed
US-20100298288-A1 CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES MERCK & CO., INC (US) 2010-11-25 US disclosed
US-20100280255-A1 PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES AMGEN INC. (US) 2010-11-04 US disclosed
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders ASTRAZENECA AB (SE) 2009-03-12 US disclosed
EP-0452267-A1 Heterocyclic compounds CIBA-GEIGY AG (CH) 1991-10-16 EP disclosed
EP-0174565-B1 PIPERIDINE DERIVATIVES AND FUNGICIDAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR COMBATING FUNGI BASF Aktiengesellschaft (DE) 1989-10-25 EP disclosed
US-4673683-A Fungicidal piperidine derivatives BASF AKTIENGESELLSCHAFT (DE) 1987-06-16 US disclosed
EP-0174565-A2 Piperidine derivatives and fungicidal compositions containing them, and process for combating fungi BASF Aktiengesellschaft (DE) 1986-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266167-A1 ERK INHIBITORS MAPK1, MAPK3, MAPK6 CYP1A2 750/4885CYP2C19 423/4885CYP3A4 776/4885
US-20100280255-A1 PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES HSD11B1, HSD11B2, HSD17B1 CYP1A2 73/4885CYP2C19 101/4885CYP3A4 90/4885
US-20100298288-A1 CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES CETP, APOB, MTTP CYP1A2 654/4885CYP2C19 892/4885CYP3A4 679/4885
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders GRIN1, GRM1, GRIN3A CYP1A2 1259/4885CYP2C19 1266/4885CYP3A4 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.